Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19652183 | 0.88 | CYP2D6 (0.53) | DRD4DRD2ACHEALDH1A1 | |
| SCHEMBL19658389 | 0.87 | ACHE (0.58) | CXCR4DRD4DRD2ACHEMEN1 | |
| SCHEMBL19652159 | 0.87 | ACHE (0.60) | ACHEBCHE | |
| SCHEMBL19652140 | 0.84 | DRD2 (0.54) | CXCR4DRD4DRD2MEN1KMT2A | |
| SCHEMBL17754013 | 0.81 | CXCR4 (0.56) | CXCR4DRD4DRD2ACHEMEN1 | |
| SCHEMBL19652286 | 0.80 | SLC6A4 (0.49) | ACHE | |
| SCHEMBL19652185 | 0.77 | ATM (0.53) | DRD4DRD2ACHEMEN1KMT2A | |
| SCHEMBL19658607 | 0.77 | CXCR4 (0.56) | CXCR4DRD4DRD2ALDH1A1 | |
| SCHEMBL14492265 | 0.76 | CXCR4 (0.62) | CXCR4DRD4DRD2ACHEMEN1 | |
| SCHEMBL19658974 | 0.75 | DRD2 (0.54) | CXCR4DRD4DRD2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | CXCR4 796/4885DRD4 3039/4885DRD2 2016/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | CXCR4 796/4885DRD4 3039/4885DRD2 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.